Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - cilostazol -

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 30 mg - tablet - excipient ingredients: magnesium stearate; indigo carmine aluminium lake; maize starch; hyprolose; microcrystalline cellulose; lactose monohydrate - samsca is indicated for the treatment of clinically significant hypervolemic or euvolemic hyponatremia (serum sodium less than 125 mmol/l, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure and syndrome of inappropriate antidiuretic hormone (siadh).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; microcrystalline cellulose; hyprolose; colour - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole orally disintegrating tablets are indicated for the treatment of: -   schizophrenia [see clinical studies (14.1)] additional pediatric use information is approved for otsuka america pharmaceutical, inc.'s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.'s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/. risk sum

United States - English - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - tolvaptan (unii: 21g72t1950) (tolvaptan - unii:21g72t1950) - jynarque is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (adpkd). jynarque is contraindicated in patients: - with a history, signs or symptoms of significant liver impairment or injury. this contraindication does not apply to uncomplicated polycystic liver disease [see warnings and precautions (5.1)] - taking strong cyp 3a inhibitors - with uncorrected abnormal blood sodium concentrations [see warnings and precautions (5.3)] - unable to sense or respond to thirst [see warnings and precautions (5.3)] - hypovolemia [see warnings and precautions (5.3)] - hypersensitivity (e.g., anaphylaxis, rash) to tolvaptan or any component of the product [see adverse reactions (6)] - uncorrected urinary outflow obstruction - anuria risk summary available data with jynarque use in pregnant women are insufficient to determine if there is a drug associated risk of adverse developmental outcomes. in embryo-fetal development studies, pregnant rats a

Philippines - English - FDA (Food And Drug Administration)

otsuka (phils.) pharmaceutical, inc. - amino acids, carbohydrates, fat emulsion, and electrolytes (see reverse) - solution for central venous infusion

United States - English - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify mycite, a drug-device combination product comprised of aripiprazole tablets embedded with an ingestible event marker (iem) sensor intended to track drug ingestion, is indicated for the: - treatment of adults with schizophrenia. - treatment of bipolar i disorder acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate. maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate. - acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate. - maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate. - adjunctive treatment of adults with major depressive disorder. limitations of use: - the ability of the abilify mycite to improve patient compliance or modify aripiprazole dosage has not been established [see dosage and administration (2.1)] . - the use of abilify mycite to track drug ingestion in "real-time" or during an emergency is not recommended

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

otsuka pharmaceutical factory, inc. - water for injection - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

otsuka pharmaceutical factory, inc. - purified glucose - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

otsuka pharmaceutical factory, inc. - purified glucose - injection